Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by Wino115on Jan 28, 2023 9:58pm
152 Views
Post# 35252405

RE:RE:RE:TH1902 ClinicalTrials.gov Update

RE:RE:RE:TH1902 ClinicalTrials.gov UpdateOne looks like a fairly standard CRO but some of the others seem to have no purpose whatsoever in a geneticaly targeted cancer drug trial. It almost appears to be a mistake listing the Montreal dermatological one and the first one, which has it's own drugs in trial and is not a CRO.  Perhaps this is some kind of clerical error by the website or something. Very odd and for such a small trial you definitely wouldn't need more than one CRO. I'm guessing that specific collab info is not accurate. 

scarlet1967 wrote:

 



They don't need more than one CRO yet most of these companies provide CRO services?? Different opinions?
Also they have removed THTX as the point of contact?? Partners? What is the company up to?
https://clinicaltrials.gov/ct2/history/NCT04706962?A=6&B=7&C=merged#StudyPageTop

 




SPCEO1 wrote: They also added "Sort1+ cancers" to the list of conditions being studied, so a broader scope.

Other than the collaborators, who may have been in place all along and were just added for completeness now, there were no significant changes. The fact they did not change the end date of the study of 3/23 may be a bit ominous, though. Clearly, the study will take longer if it restarts.I imagine they cannot put a new end date in until they actually know what the new study approach entails. So, maybe it is not r eally all that ominous.
SABBOBCAT wrote:

Looks like they finally updated the clinicaltrials.gov listing yesterday. There was an interesting tidbit in the collaborators section. It now lists altasciences, Windtree Therapeutics, Syneos Health, and Innovaderm Research Inc.

Perhaps some the more scientifically minded posters here can spool up some interesting theories as to what these relationships could be. Some of them are CRO based, but what stands out to me is some are specializing in dermatology and cardiovascular therapies. 




 



<< Previous
Bullboard Posts
Next >>